证券代码：688573 证券简称：信宇人 公告编号：2025-051 深圳市信宇人科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 会议召开和出席情况 重要内容提示： 本次会议是否有被否决议案：无 （一） 股东会召开的时间：2025 年 12 月 8 日 （二） 股东会召开的地点：惠州仲恺高新区东江高新科技产业园兴启西路 3 号 惠州信宇人一号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 普通股股东人数 | 69 | | 2、出席会议的股东所持有的表决权数量 | 45,526,635 | | 普通股股东所持有表决权数量 | 45,526,635 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 48.2821 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 48.2821 | 注：截 ...

信宇人公告，公司募投项目"惠州信宇人研发中心建设项目"新增实施主体为母公司深圳市信宇人科技股 份有限公司，同时新增实施地点为深圳市龙岗区。 ...

首版商业健康保险创新药品目录发布 摄/宋婕 礼来制药有限公司中国总裁兼总经理德赫兰表示，公司将在中国推出20余款新产品和新适应证，持续聚焦那些未被满足需求的最为迫切、准入壁垒最高的疾 病领域。此外，公司还将推动全球同步上市，让中国患者与全球零时差共享创新。 基本医保和商保形成"组合拳"，制度创新推动创新药研发与应用。 12月7日，2025创新药高质量发展大会在广州举行。国家医疗保障局党组书记、局长章轲在致辞时表示，回望过去的十年，在社会各界的共同努力下，中国 医药创新从远观、紧跟到起步、并肩，并在部分领域实现了反超、领跑。1到10月，中国创新药的海外授权超过了700例，金额突破了1000亿美元。产业的发 展也带来了临床应用水平、医疗保障项目和群众健康水平的明显提升。 2025年国家基本医疗保险、生育保险和工伤保险药品目录，以及首版商业健康保险创新药品目录在大会现场发布。2025年国家医保药品目录新增114种药 品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。此外，19种药品纳入首版商保创新药目录，涵盖CAR-T等肿瘤治疗药品，也有神经 母细胞瘤、戈谢病等罕见病治疗药品，还有阿尔茨海默 ...

Group 1 - The company emphasizes the importance of shareholder rights and acknowledges that secondary market performance is significantly influenced by macroeconomic conditions, market preferences, and investor expectations [1] - The company plans to leverage a "equipment + technology + materials" integrated approach to further develop its capabilities in high-end intelligent manufacturing equipment research, production, and sales [1] - The company aims to improve its operational performance to provide better returns to shareholders in the future [1]

Core Viewpoint - The company is experiencing a significant increase in orders and is actively working to expand its production capacity to meet future market demand for lithium battery equipment, particularly driven by the growth in the electric vehicle and energy storage markets [1] Group 1: Company Operations - The company currently has a large number of orders on hand, with production capacity utilization remaining at a high level [1] - The construction progress of the second production park in Huizhou is being accelerated to alleviate delivery pressure caused by the substantial increase in orders [1] Group 2: Market Demand - There is a clear growth in demand for lithium batteries from downstream markets, particularly in the electric vehicle and energy storage sectors [1] - The demand for lithium battery equipment is expected to continue to grow over the next 2-3 years, driven by the replacement of retired equipment and production line upgrades [1]

深圳市信宇人科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688573 证券简称：信宇人 深圳市信宇人科技股份有限公司 ShenzhenXinyurenTechnologyCo.,Ltd. 2025 年第三次临时股东会 会议资料 二〇二五年十二月 | 2025 | 年第三次临时股东会会议议程 4 | | --- | --- | | 2025 | 年第三次临时股东会会议议案 6 | | | 议案一：《关于聘任会计师事务所的议案》 6 | 深圳市信宇人科技股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会会议须知 为维护广大投资者的合法权益，保障股东在本次股东会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东会规则》和公司《股东会议事规则》 等有关规定，特制定本会议须知： 一、公司负责本次股东会的议程安排和会务工作，为确认出席会议的股东或 其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行必 要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示本人有效身份证或营业 ...

Core Viewpoint - The company XinYuren experienced a decline in stock price by 1.47% on November 26, with a trading volume of 36.71 million yuan, indicating potential investor concerns regarding its financial performance and market position [1]. Financing Summary - On November 26, XinYuren had a financing buy-in amount of 7.41 million yuan, with a net financing buy of 3.06 million yuan after 4.35 million yuan in financing repayments. The total financing and margin balance reached 90.61 million yuan, accounting for 7.25% of its market capitalization, which is above the 50th percentile level over the past year, indicating a relatively high financing level [1]. - The company had no short selling activity on the same day, with a short selling balance of 0.00 shares, placing it in the 90th percentile level over the past year, suggesting a lack of bearish sentiment among investors [1]. Business Performance - As of September 30, the number of shareholders for XinYuren increased by 5.27% to 8,315, while the average circulating shares per person decreased by 2.77% to 6,400 shares [2]. - For the period from January to September 2025, XinYuren reported a revenue of 94.75 million yuan, a significant year-on-year decrease of 50.12%. The net profit attributable to shareholders was -15.7 million yuan, reflecting a drastic decline of 106.31% compared to the previous year [2]. Dividend and Shareholding Structure - Since its A-share listing, XinYuren has distributed a total of 19.37 million yuan in dividends [3]. - As of September 30, 2025, among the top ten circulating shareholders, Yuanxin Yongfeng High-end Manufacturing A (006969) emerged as the eighth largest shareholder with 364,100 shares, marking its entry as a new shareholder. Meanwhile, Zhonghai Energy Strategy Mixed (398021) and Jinying Reform Dividend Mixed (001951) exited the top ten list [3].

Group 1 - The company, Xinyu, stated on November 24 that it will disclose the number of shareholders at the end of the reporting period in its regular reports to ensure all investors receive information equally [2]

Group 1 - The company will hold its third extraordinary general meeting of shareholders on December 8, 2025, at 14:30 [2][5] - The meeting will take place at the company's conference room located in Huizhou [2] - Shareholders can vote through the Shanghai Stock Exchange's online voting system on the day of the meeting [3][4] Group 2 - The company plans to appoint Shanghai Huikai Certified Public Accountants as its new auditing firm for the 2025 fiscal year, replacing Zhengdan Zhiyuan [20][21] - The change in auditing firms is aimed at better aligning with the company's future business development and ensuring effective audit arrangements [21][31] - The proposed auditing fee for 2025 is set at 1.2 million yuan, which includes 250,000 yuan for internal control auditing [30]

证券代码：688573 证券简称：信宇人 公告编号：2025-049 深圳市信宇人科技股份有限公司 关于聘任会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为充分保障深圳市信宇人科技股份有限公司（以下简称"公司"）审计工作安 排，更好地适应公司未来业务发展，综合考虑市场信息，基于审慎性原则以及公 司对审计服务的需求，根据《国有企业、上市公司选聘会计师事务所管理办法》 的相关规定，经履行相应的选聘程序并根据评估结果，公司拟聘任上会所为公司 2025 年度财务报告审计机构以及内部控制审计机构。公司已就本次变更会计师 事务所事项与政旦志远进行充分沟通，政旦志远对本次变更事项无异议。 本事项尚需提交公司 2025 年第三次临时股东会审议。 一、拟聘任会计师事务所的基本情况 (一)机构信息 1.基本信息 机构名称：上会会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 27 日 组织形式：特殊普通合伙企业 拟聘任的会计师事务所名称：上会会计师事务所（特殊普通合伙）（以下简 称"上会所" ...